# HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors

> **NCT06822998** · EARLY_PHASE1 · RECRUITING · sponsor: **HighField Biopharmaceuticals Corporation** · enrollment: 10 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** HF50

## Key facts

- **NCT ID:** NCT06822998
- **Lead sponsor:** HighField Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-11
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06822998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06822998, "HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06822998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*